English Polski
Vol 15, No 2 (2022)
Review paper
Published online: 2022-07-12

open access

Page views 2021
Article views/downloads 910
Get Citation

Connect on Social Media

Connect on Social Media

DOAC — nie u każdego i czasem w innych dawkach

Jacek Musiał
Journal of Transfusion Medicine 2022;15(2):154-158.

Abstract

Doustne bezpośrednie inhibitory krzepnięcia (DOAC) stosuje się w Europie już od ponad 10 lat. Jedną z ich istotnych zalet jest stosowanie w profilaktyce i leczeniu stałych dawek leków. Niekiedy preferuje się jednak starsze leki przeciwzakrzepowe (antywitaminy K, heparyny) lub w pewnych sytuacjach klinicznych modyfikuje się standardowe, zalecane dawki DOAC.

Article available in PDF format

View PDF (Polish) Download PDF file

References

  1. Jame S, Barnes G. Stroke and thromboembolism prevention in atrial fibrillation. Heart. 2020; 106(1): 10–17.
  2. Ortel TL, Neumann I, Ageno W, et al. American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism. Blood Adv. 2020; 4(19): 4693–4738.
  3. Bayer V, Kotalczyk A, Kea B, et al. Global Oral Anticoagulation Use Varies by Region in Patients With Recent Diagnosis of Atrial Fibrillation: The GLORIA-AF Phase III Registry. J Am Heart Assoc. 2022; 11(6): e023907.
  4. Woller SC, Stevens SM, Kaplan D, et al. Apixaban compared with warfarin to prevent thrombosis in thrombotic antiphospholipid syndrome: a randomized trial. Blood Adv. 2022; 6(6): 1661–1670.
  5. Pengo V, Denas G, Zoppellaro G, et al. Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome. Blood. 2018; 132(13): 1365–1371.
  6. Martinelli I, Abbattista M, Bucciarelli P, et al. Recurrent thrombosis in patients with antiphospholipid antibodies treated with vitamin K antagonists or rivaroxaban. Haematologica. 2018; 103(7): e315–e317.
  7. Ordi-Ros J, Sáez-Comet L, Pérez-Conesa M, et al. Rivaroxaban Versus Vitamin K Antagonist in Antiphospholipid Syndrome: A Randomized Noninferiority Trial. Ann Intern Med. 2019; 171(10): 685–694.
  8. Pastori D, Menichelli D, Cammisotto V, et al. Use of Direct Oral Anticoagulants in Patients With Antiphospholipid Syndrome: A Systematic Review and Comparison of the International Guidelines. Front Cardiovasc Med. 2021; 8: 715878.
  9. Chan KE, Edelman ER, Wenger JB, et al. Dabigatran and rivaroxaban use in atrial fibrillation patients on hemodialysis. Circulation. 2015; 131(11): 972–979.
  10. Wang X, Tirucherai G, Marbury TC, et al. Pharmacokinetics, pharmacodynamics, and safety of apixaban in subjects with end-stage renal disease on hemodialysis. J Clin Pharmacol. 2016; 56(5): 628–636.
  11. Wadsworth D, Sullivan E, Jacky T, et al. A review of indications and comorbidities in which warfarin may be the preferred oral anticoagulant. J Clin Pharm Ther. 2021; 46(3): 560–570.
  12. Cheung CYS, Parikh J, Farrell A, et al. Direct Oral Anticoagulant Use in Chronic Kidney Disease and Dialysis Patients With Venous Thromboembolism: A Systematic Review of Thrombosis and Bleeding Outcomes. Ann Pharmacother. 2021; 55(6): 711–722.
  13. Nishimura RA, Otto CM, Bonow RO, et al. 2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2017; 135(25): e1159–e1195.
  14. Eikelboom JW, Connolly SJ, Brueckmann M, et al. RE-ALIGN Investigators. Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med. 2013; 369(13): 1206–1214.
  15. Connolly S, Ezekowitz M, Yusuf S, et al. Dabigatran versus Warfarin in Patients with Atrial Fibrillation. N Engl J Med . 2009; 361(12): 1139–1151.
  16. Connolly S, Eikelboom J, Joyner C, et al. Apixaban in Patients with Atrial Fibrillation. N Engl J Med. 2011; 364(9): 806–817.
  17. Camm A, Cools F, Virdone S, et al. Mortality in Patients With Atrial Fibrillation Receiving Nonrecommended Doses of Direct Oral Anticoagulants. J Am Coll Cardiol. 2020; 76(12): 1425–1436.
  18. Carlin S, Eikelboom JW. Direct oral anticoagulant dose selection: Challenging cases. J Thromb Haemost. 2021; 19(11): 2680–2686.
  19. Bingzheng X, Jingnan R, Ligang B, et al. The effects of anticoagulant therapy re-initiation after gastrointesitinal bleeding: a systematic review and meta-analysis. J Clin Pharm Ther. 2021; 46(6): 1509–1518.
  20. Xu Y, Siegal DM. Anticoagulant-associated gastrointestinal bleeding: Framework for decisions about whether, when and how to resume anticoagulants. J Thromb Haemost. 2021; 19(10): 2383–2393.
  21. Agnelli G, Buller HR, Cohen A, et al. AMPLIFY-EXT Investigators. Apixaban for extended treatment of venous thromboembolism. N Engl J Med. 2013; 368(8): 699–708.
  22. Weitz J, Lensing A, Prins M, et al. Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism. N Engl J Med . 2017; 376(13): 1211–1222.